StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $1.55 | $1.57 | +1.29% | 1.6M |
| 05-12 | $1.58 | $1.58 | +0.00% | 0.6M |
| 05-13 | $1.58 | $1.48 | -6.33% | 0.9M |
| 05-14 | $1.48 | $1.43 | -3.38% | 1.2M |
| 05-15 | $1.42 | $1.35 | -4.93% | 1.9M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 | Q1 2022 2022-03-31 | Q3 2021 2021-09-30 |
|---|---|---|---|---|
Revenue | $1.24B | $1.07B | $1.07B | $1.07B |
Operating Income | $-23.48M | $-17.47M | $-16.40M | $-12.64M |
Net Income | $-22.89M | $-17.26M | $-16.37M | $-12.61M |
EPS (Diluted) | $-0.78 | $-0.59 | $-0.56 | $-0.43 |
Total Assets | $145.05M | $161.74M | $174.86M | $199.40M |
Total Liabilities | $14.41M | $11.35M | $10.10M | $8.07M |
Cash & Equivalents | $132.31M | $148.48M | $156.22M | $156.97M |
Free Cash Flow OCF − CapEx | $-42.53M | $-25.79M | $-10.09M | $-22.42M |
Shares Outstanding | 29.39M | 29.28M | 29.17M | 29.04M |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.